文献速递生殖医学

含邻苯二甲酸酯药物使用与辅助生殖夫妇中男性精液质量的关联

Association between use of phthalate-containing medication and semen quality among men in couples referred for assisted reproduction.
PubMed 文献 · Hum Reprod · 2018-01-01

基于丹麦体外受精登记库2006至2016年18515例精液质量差男性和31063例精液质量正常男性,评估采样前90天内使用含邻苯二甲酸酯或聚合物药物的暴露与精液质量的关联。调整混杂后,含邻苯二甲酸酯药物暴露与精液质量差的比值比为1.30(95%CI 0.91-1.85),含聚合物药物暴露的比值比为1.71(95%CI 1.24-2.35)。

要点

  • 精液采样前90天内使用含邻苯二甲酸酯药物与精液质量差的调整OR为1.30(95%CI 0.91-1.85)。
  • 使用含聚合物药物与精液质量差的调整OR为1.71(95%CI 1.24-2.35)。
  • 消化系统与代谢药物中含聚合物产品的当前暴露OR最高,为2.80(95%CI 1.63-4.84)。

核心结论

  • 含邻苯二甲酸酯药物暴露与精液质量差存在关联。
  • 作者认为结果支持药物来源的邻苯二甲酸酯暴露对精液质量的可能负面影响,且药物暴露易于避免,可能对监管机构有参考意义。

研究设计与样本

  • 基于丹麦体外受精登记库2006至2016年的病例对照研究,纳入18515例精液质量差的男性(病例)和31063例精液质量正常的男性(对照)。
  • 暴露评估来自丹麦药品统计登记库,采用非条件logistic回归分析,并调整潜在混杂因素。

主要发现

  • 共57例病例和72例对照在首次精液采样前90天内至少配取过一次含邻苯二甲酸酯药物,与使用不含邻苯二甲酸酯仿制药的男性相比,精液质量差的调整OR为1.30(95%CI 0.91-1.85)。
  • 共81例病例和78例对照暴露于含聚合物药物,精液质量差的OR为1.71(95%CI 1.24-2.35)。
  • 消化系统与代谢药物中含聚合物产品的当前暴露与最高的OR相关,为2.80(95%CI 1.63-4.84)。
  • 与未暴露于处方药的男性相比,暴露于含邻苯二甲酸酯药物或含聚合物药物的男性精液质量差的调整OR分别为1.32(95%CI 0.93-1.87)和1.73(95%CI 1.26-2.36)。
  • 未观察到暴露程度与精液质量差比值比之间的明确关系。

局限性

  • 依赖基于ICD-10的登记数据限制了将邻苯二甲酸酯暴露与详细精液参数相关联的能力。
  • 由于登记库不完善,仅能纳入首次精液样本,无法随时间随访精液质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does phthalate exposure from prescription drugs affect semen quality? SUMMARY ANSWER: Exposure to phthalate-containing drugs is associated with poor semen quality. WHAT IS KNOWN ALREADY: Phthalates and their metabolites have been shown to disrupt the hormone signalling in animal studies. One study has shown associations between medicinal phthalate exposure and poor semen quality, suggesting similar effects in humans. STUDY DESIGN, SIZE, DURATION: We included 18 515 males with poor semen quality (cases) and 31 063 males with normal semen quality (controls) registered in the Danish IVF Registry from 2006 to 2016. PARTICIPANTS/MATERIALS, SETTING, METHODS: Exposure to phthalate-containing drugs was assessed from the Danish Register of Medicinal Product Statistics. Outcome measures were obtained at the first contact with the fertility clinic, and categorized according to the International Classification of Diseases (ICD-10). The association between current use of phthalate-containing medications <90 days prior to semen sampling and reduced semen quality was analysed using unconditional logistic regression, adjusting for potential confounders. MAIN RESULTS AND THE ROLE OF CHANCE: In total, 57 cases and 72 controls redeemed at least one prescription for a drug containing ortho-phthalates in the 90 days before their first semen sample, yielding an adjusted odds ratio (OR) of 1.30 (95% CI: 0.91-1.85) for poor semen quality when compared to males exposed to phthalate-free generic drugs. Similarly, 81 cases and 78 controls exposed to a drug containing polymers had increased odds of poor semen quality (OR = 1.71, 95% CI: 1.24-2.35). Current exposure to polymer containing products from alimentary tract and metabolism drugs was associated with the highest OR of 2.80 (95% CI: 1.63-4.84). Comparing males exposed to drugs containing ortho-phthalates or polymers with males unexposed to prescription drugs, we found adjusted ORs of 1.32 (95% CI: 0.93-1.87) and 1.73 (95% CI: 1.26-2.36), respectively. We saw no clear relationship between degree of exposure and odds of poor semen quality. LIMITATIONS, REASONS FOR CAUTION: The reliance on ICD-10 based register data restricted our ability to relate phthalate exposure to detailed semen parameters. Furthermore, due to imperfections in the registry, we could only include the first semen sample and could not follow semen quality over time. WIDER IMPLICATIONS OF THE FINDINGS: Our results support the likely negative effect of phthalate exposure from medicinal drugs on semen quality. As exposures from medicinal products are readily avoidable, our findings may be of relevance to regulatory authorities. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by Odense University Hospital, Denmark (Grant number A1003). None of the authors declare conflict of interest.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Broe A, Pottegård A, Hallas J, et al. Association between use of phthalate-containing medication and semen quality among men in couples referred for assisted reproduction. Hum Reprod. 2018. PMID: 29425332. doi:10.1093/humrep/dey009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。